Study #2020-1061
Phase 1B/2 Open-Label, Multicenter, Dose Optimization Clinical Study Of The Safety, Tolerability, And Pharmacokinetic And Pharmacodynamic Profiles Of CFI-400945 As A Single Agent Or In Combination With Azacitidine Or Decitabine In Patients With Acute Myel
MD Anderson Study Status
Enrolling
Treatment Agent
CFI-400945, Azacitidine
Description
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Study phase:
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.